Stock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price

Stock Track11-10

Shares of Amylyx Pharmaceuticals (AMLX) surged 5.61% in pre-market trading on Monday, following a positive adjustment in its target price by Mizuho analysts. The biotech company, known for its focus on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, saw its stock climb on the heels of this encouraging analyst action.

Mizuho raised its target price for Amylyx Pharmaceuticals from $16 to $18, signaling increased confidence in the company's future prospects. This upward revision likely contributed to the pre-market rally, as investors responded positively to the more optimistic valuation.

The increase in target price could reflect growing optimism about Amylyx's drug pipeline or recent developments in its research and development efforts. While specific reasons for the target price adjustment were not provided in the news, such changes often stem from improved outlooks on a company's financial performance, market position, or potential breakthroughs in drug development. Investors will be watching closely to see if this pre-market momentum carries into regular trading hours and whether Amylyx can sustain this upward trend.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128500495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128500495","market":"nz","top_or_hot":-1,"title":"Stock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price","media":"Stock Track","content":"<p>Shares of Amylyx Pharmaceuticals (AMLX) surged 5.61% in pre-market trading on Monday, following a positive adjustment in its target price by Mizuho analysts. The biotech company, known for its focus on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, saw its stock climb on the heels of this encouraging analyst action.</p>\n\n<p>Mizuho raised its target price for Amylyx Pharmaceuticals from $16 to $18, signaling increased confidence in the company's future prospects. This upward revision likely contributed to the pre-market rally, as investors responded positively to the more optimistic valuation.</p>\n\n<p>The increase in target price could reflect growing optimism about Amylyx's drug pipeline or recent developments in its research and development efforts. While specific reasons for the target price adjustment were not provided in the news, such changes often stem from improved outlooks on a company's financial performance, market position, or potential breakthroughs in drug development. Investors will be watching closely to see if this pre-market momentum carries into regular trading hours and whether Amylyx can sustain this upward trend.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-10 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Amylyx Pharmaceuticals (AMLX) surged 5.61% in pre-market trading on Monday, following a positive adjustment in its target price by Mizuho analysts. The biotech company, known for its focus on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, saw its stock climb on the heels of this encouraging analyst action.</p>\n\n<p>Mizuho raised its target price for Amylyx Pharmaceuticals from $16 to $18, signaling increased confidence in the company's future prospects. This upward revision likely contributed to the pre-market rally, as investors responded positively to the more optimistic valuation.</p>\n\n<p>The increase in target price could reflect growing optimism about Amylyx's drug pipeline or recent developments in its research and development efforts. While specific reasons for the target price adjustment were not provided in the news, such changes often stem from improved outlooks on a company's financial performance, market position, or potential breakthroughs in drug development. Investors will be watching closely to see if this pre-market momentum carries into regular trading hours and whether Amylyx can sustain this upward trend.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMLX","symbol_name":"Amylyx Pharmaceuticals","start_time":0,"source_url":"","article_id":"1128500495","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128500495","pubTimestamp":1762780235,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Amylyx Pharmaceuticals (AMLX) surged 5.61% in pre-market trading on Monday, following a positive adjustment in its target price by Mizuho analysts. The biotech company, known for its focus...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMLX":"Amylyx Pharmaceuticals"},"translate_title":"个股追踪|瑞穗上调目标价Amylyx制药盘前大涨5.61%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":1},"content_text":"Shares of Amylyx Pharmaceuticals (AMLX) surged 5.61% in pre-market trading on Monday, following a positive adjustment in its target price by Mizuho analysts. The biotech company, known for its focus on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, saw its stock climb on the heels of this encouraging analyst action.\nMizuho raised its target price for Amylyx Pharmaceuticals from $16 to $18, signaling increased confidence in the company's future prospects. This upward revision likely contributed to the pre-market rally, as investors responded positively to the more optimistic valuation.\nThe increase in target price could reflect growing optimism about Amylyx's drug pipeline or recent developments in its research and development efforts. While specific reasons for the target price adjustment were not provided in the news, such changes often stem from improved outlooks on a company's financial performance, market position, or potential breakthroughs in drug development. Investors will be watching closely to see if this pre-market momentum carries into regular trading hours and whether Amylyx can sustain this upward trend.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128500495","isCrawlerRequest":true}